CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)

neflamapimod (VX-745) - CervoMed

Aug 4, 2026